American Herbal Products Association (AHPA) > News > AHPA in the News

AHPA in the News

July 2019 AHPA in the News

AHPA urges FDA to protect consumers by quickly clarifying hemp-CBD regulations

Existing supplement and food regulations are sufficiently robust for hemp-derived ingredients

The American Herbal Products Association (AHPA) urged the Food and Drug Administration (FDA) last week to protect consumers by quickly taking specific actions to clarify the regulatory status of hemp and hemp-derived ingredients used in dietary supplements and foods that contain cannabidiol (CBD).

AHPA recommends FDA implement policies to support innovation

The American Herbal Products Association (AHPA) submitted extensive and specific policy recommendations on July 15 to the Food and Drug Administration (FDA) to support responsible dietary supplement innovation while preserving and strengthening FDA’s ability to efficiently and effectively protect the public from unsafe and unlawful products.

June 2019 AHPA in the News

Sen. Wyden urges HHS-FDA to issue interim final rule for lawful use of CBD in food and dietary supplements

Sen. Wyden urges HHS-FDA to issue interim final rule for lawful use of CBD in food and dietary supplements

Sen. Wyden's request aligns with AHPA's hemp-CBD advocacy

Sen. Ron Wyden (D-OR), a co-author of the hemp provisions included in the 2018 Farm Bill, sent letters to Food and Drug Administration (FDA) Commissioner Ned Sharpless and Health & Human Services (HHS) Secretary Alex Azar urging the agencies to promptly create a regulatory pathway to use cannabidiol (CBD) as a food additive and as a dietary ingredient in dietary supplements.

AHPA President Michael McGuffin presents on CA regulations that impact the supplement industry at ACI Conference

AHPA provides several resources to help navigate CA regulations

American Herbal Products Association (AHPA) President Michael McGuffin discussed significant California regulations that impact the dietary supplement industry at the American Conference Institute's (ACI's) seventh annual Legal, Regulatory, and Compliance Forum on Dietary Supplements held in New York City June 18-20.

AHPA urges USTR to exempt herbal product ingredients from proposed China tariff increases

Herbal ingredients should be excluded from tariff increases because supplements and food play important roles in the health of U.S. consumers

The American Herbal Products Association (AHPA) urged the U.S. Trade Representative (USTR) to remove herbal product ingredients from a list of Chinese goods that would be subject to a 25 percent ad valorem duty under a recent USTR proposal to increase tariffs on an estimated $300 billion worth of Chinese imports.
AHPA presents at 2019 NIH ODS Dietary Supplement Research Practicum

AHPA presents at 2019 NIH ODS Dietary Supplement Research Practicum

Dr. Zimmermann highlights industry actions to ensure safe and high-quality herbal supplements to medical professionals and researchers

AHPA Chief Information Analyst Merle Zimmermann, Ph.D. presented last week at the Mary Frances Picciano Dietary Supplement Research Practicum held by the Office of Dietary Supplements (ODS) at the National Institutes of Health (NIH) campus in Bethesda, MD.
AHPA staff and members present at regulatory summit, USP, FDA-CFSAN and more

AHPA staff and members present at regulatory summit, USP, FDA-CFSAN and more

AHPA provides expertise in hemp-CBD, regulatory initiatives, pesticide residues, NDIs and food allergens

U.S. increases and proposes expansion of tariffs on Chinese imports

China announces additional tariffs on any plant mainly used as a spice

The U.S. Trade Representative (USTR) announced on May 9 that it increased tariffs on approximately $200 billion worth of Chinese imports initially identified in September 2018 from 10 percent to 25 percent.
RSS
12345

2019 Annual Fund Sponsors

AHPA appreciates the support of its sponsors, but does not endorse, recommend, or provide a warranty for any sponsor company, its products or services. AHPA has no responsibility for any transaction entered into with any of these companies.